Dionysus Digital Health Presentation at the Non-Dilutive Funding Summit
The 21st Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with representatives from some of the leading funding agencies including ARPA-H, BARDA, CPRIT, CIRM, Breakthrough T1D and more, giving attendees the opportunity to learn more in-depth about what non-dilutive funding opportunities are available and relevant for their R&D directly from the funding agencies.
Additionally, the 2025 FreeMind Elite honorees took to the stage to present about their companies research and pipelines and their journey to securing non-dilutive funding.
This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences.
Dionysus Digital Health
The First Blood Test to Predict Postpartum Depression (PPD) is here. Untreated perinatal depression costs the U.S. $14 billion annually. 1 in 5 new mothers experience PPD.Only 20% of OBs conduct prenatal PPD screening, despite legal mandates. Our test solves this gap predictive, validated, FDA-ready, and revenue-generating. My Luma™ is the first clinically validated prenatal biomarker blood test, leveraging epigenetics and artificial intelligence to predict a woman’s risk of postpartum depression as early as 28th weeks of her pregnancy. We see the crisis. We understand the stakes. We developed science to change everything
